CO6210819A2 - Agonistas de adrenoreceptores alfa2c funcionalmente selectivos - Google Patents
Agonistas de adrenoreceptores alfa2c funcionalmente selectivosInfo
- Publication number
- CO6210819A2 CO6210819A2 CO09084449A CO09084449A CO6210819A2 CO 6210819 A2 CO6210819 A2 CO 6210819A2 CO 09084449 A CO09084449 A CO 09084449A CO 09084449 A CO09084449 A CO 09084449A CO 6210819 A2 CO6210819 A2 CO 6210819A2
- Authority
- CO
- Colombia
- Prior art keywords
- heterocyclyl
- independently
- optionally substituted
- double bond
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
Abstract
1.- Un compuesto de fórmula:o una sal, éster, solvato o profármaco del mismo, farmacéuticamente aceptable donde: J1, J2, y J3 son independientemente -N-, -N(O)-o -C(R2)-;J4 es:donde: J es -C-, -N-, o -C(R6)-; Z es-[C(Ra)(Ra)]x-;donde Ra es independientemente H o alquilo; y x es 1, 2, o 3; J5 es -C(R6')-, -N(R6')-, -O- o-S-; A es un anillo heteroarilo, heterociclilo o heterociclenilo de 5 miembros que contiene 1-3 heteroátomos, y está opcionalmente sustituido con por lo menos un R5 y/o 1 o 2 grupos (=O) (carbonilo); J1, J2, y J3 son independientemente -N-, -N(O)-o -C(R2)-; J4 es C, N, o -C(R6)-;J5 es -C(R6')-, -N(R6')-, -O- o -S- con la condición de que un enlace doble no está presente entre J5 y un átomo de anillo adyacente cuando J5 es -O- o -S-;----- es un enlace único o doble con la condición de que no puede haber dos enlaces dobles continuos y con la condición adicional de que cuando los átomos 1 y 2 forman un doble enlace, R4' no está presente; R1 es un anillo seleccionado del grupo que consiste en cicloalquilo, cicloalquenilo, arilo, heterocíclilo, heterociclenilo, y heteroarilo, cada uno de los cuales está opcionalmente sustituido con por lo menos un R12;R2 está seleccionado independientemente del grupo que consiste en H, -OH, halo, CN, NO2, S(O)pR7, NR7R7', (CH2)qYR7', -(CH2)qN(R7)YR7', -(CH2)qOYR7', y -(CH2)qONCR7R7', y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo opcionalmente sustituidos con por lo menos un R5; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90104507P | 2007-02-13 | 2007-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6210819A2 true CO6210819A2 (es) | 2010-10-20 |
Family
ID=39690680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09084449A CO6210819A2 (es) | 2007-02-13 | 2009-08-12 | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos |
Country Status (19)
Country | Link |
---|---|
US (1) | US8501747B2 (es) |
EP (1) | EP2125749A2 (es) |
JP (1) | JP2010518159A (es) |
KR (1) | KR20090113326A (es) |
CN (1) | CN101702905A (es) |
AR (1) | AR065307A1 (es) |
AU (1) | AU2008216797A1 (es) |
BR (1) | BRPI0807961A2 (es) |
CA (1) | CA2678036A1 (es) |
CL (1) | CL2008000430A1 (es) |
CO (1) | CO6210819A2 (es) |
EC (1) | ECSP099579A (es) |
IL (1) | IL200395A0 (es) |
MX (1) | MX2009008775A (es) |
PE (1) | PE20081781A1 (es) |
RU (1) | RU2009134059A (es) |
TW (1) | TW200838505A (es) |
WO (1) | WO2008100456A2 (es) |
ZA (1) | ZA200906128B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009008776A (es) | 2007-02-13 | 2009-08-25 | Schering Corp | Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
CN101702905A (zh) | 2007-02-13 | 2010-05-05 | 先灵公司 | 功能选择性α2C肾上腺素能受体激动剂 |
JP2010518161A (ja) | 2007-02-13 | 2010-05-27 | シェーリング コーポレイション | 機能選択性α2Cアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体 |
US8383818B2 (en) | 2008-02-21 | 2013-02-26 | Merck Sharp & Dohme Corp. | Functionally selective alpha2C adrenoreceptor agonists |
TW201026672A (en) * | 2008-10-07 | 2010-07-16 | Schering Corp | Spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
WO2010042473A1 (en) | 2008-10-07 | 2010-04-15 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
DK2669270T3 (en) | 2011-01-28 | 2018-02-26 | Sato Pharma | Indole-related compounds such as URAT1 inhibitors |
WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
EP3735419A4 (en) | 2018-01-05 | 2021-09-15 | Icahn School of Medicine at Mount Sinai | PROCESS FOR INCREASING THE PROLIFERATION OF PANCREATIC BETA CELLS, PROCESS OF TREATMENT AND COMPOSITION |
EP3768267A4 (en) | 2018-03-20 | 2022-04-20 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
JP2022515652A (ja) * | 2018-12-31 | 2022-02-21 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
ES2216339T3 (es) | 1997-12-04 | 2004-10-16 | Allergan, Inc. | Derivados sustituidos de imidazol que tienen actividad de tipo agonista hacia los receptores adrenergicos alfa 2b o 2b/2c. |
TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
FR2821358B1 (fr) | 2001-02-27 | 2006-04-07 | Aventis Pharma Sa | Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique |
WO2005005781A1 (en) | 2003-07-14 | 2005-01-20 | Elthom Enterprises Limited | Volume screw machine of rotary type |
US8003624B2 (en) * | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
ATE478069T1 (de) | 2005-08-25 | 2010-09-15 | Schering Corp | 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten |
BRPI0615307A2 (pt) * | 2005-08-25 | 2009-08-04 | Schering Corp | agonistas de adrenorreceptor alfa2c |
US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
ES2338716T3 (es) | 2006-01-27 | 2010-05-11 | F.Hoffmann-La Roche Ag | Uso de derivados de 4-imidazol para trastornos del snc. |
MX2009008776A (es) | 2007-02-13 | 2009-08-25 | Schering Corp | Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
CN101702905A (zh) | 2007-02-13 | 2010-05-05 | 先灵公司 | 功能选择性α2C肾上腺素能受体激动剂 |
JP2010518161A (ja) | 2007-02-13 | 2010-05-27 | シェーリング コーポレイション | 機能選択性α2Cアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体 |
-
2008
- 2008-02-11 CN CN200880011940A patent/CN101702905A/zh active Pending
- 2008-02-11 MX MX2009008775A patent/MX2009008775A/es unknown
- 2008-02-11 BR BRPI0807961A patent/BRPI0807961A2/pt not_active IP Right Cessation
- 2008-02-11 RU RU2009134059/04A patent/RU2009134059A/ru unknown
- 2008-02-11 CA CA002678036A patent/CA2678036A1/en not_active Abandoned
- 2008-02-11 US US12/525,641 patent/US8501747B2/en not_active Expired - Fee Related
- 2008-02-11 EP EP08714238A patent/EP2125749A2/en not_active Withdrawn
- 2008-02-11 CL CL200800430A patent/CL2008000430A1/es unknown
- 2008-02-11 AU AU2008216797A patent/AU2008216797A1/en not_active Abandoned
- 2008-02-11 JP JP2009549594A patent/JP2010518159A/ja active Pending
- 2008-02-11 WO PCT/US2008/001765 patent/WO2008100456A2/en active Application Filing
- 2008-02-11 KR KR1020097018915A patent/KR20090113326A/ko not_active Application Discontinuation
- 2008-02-12 PE PE2008000302A patent/PE20081781A1/es not_active Application Discontinuation
- 2008-02-12 AR ARP080100593A patent/AR065307A1/es not_active Application Discontinuation
- 2008-02-12 TW TW097104902A patent/TW200838505A/zh unknown
-
2009
- 2009-08-12 CO CO09084449A patent/CO6210819A2/es not_active Application Discontinuation
- 2009-08-13 EC EC2009009579A patent/ECSP099579A/es unknown
- 2009-08-13 IL IL200395A patent/IL200395A0/en unknown
- 2009-09-03 ZA ZA200906128A patent/ZA200906128B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010518159A (ja) | 2010-05-27 |
TW200838505A (en) | 2008-10-01 |
CN101702905A (zh) | 2010-05-05 |
PE20081781A1 (es) | 2008-12-18 |
WO2008100456A3 (en) | 2008-11-06 |
CL2008000430A1 (es) | 2008-08-18 |
MX2009008775A (es) | 2010-03-01 |
ECSP099579A (es) | 2009-09-29 |
AU2008216797A1 (en) | 2008-08-21 |
RU2009134059A (ru) | 2011-03-20 |
KR20090113326A (ko) | 2009-10-29 |
WO2008100456A2 (en) | 2008-08-21 |
AR065307A1 (es) | 2009-05-27 |
EP2125749A2 (en) | 2009-12-02 |
US8501747B2 (en) | 2013-08-06 |
ZA200906128B (en) | 2010-06-30 |
CA2678036A1 (en) | 2008-08-21 |
BRPI0807961A2 (pt) | 2017-05-16 |
IL200395A0 (en) | 2010-04-29 |
US20100197562A1 (en) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6210819A2 (es) | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos | |
AR056043A1 (es) | Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos | |
CO4900063A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 | |
AR065310A1 (es) | Agonistas de adrenoreceptores alfa2c | |
CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
HUP0303296A2 (hu) | Karboxamidszármazékok és ezek alkalmazása tromboembóliás betegségek és tumorok kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
AR065311A1 (es) | Agonistas del adrenoreceptor alfa2c funcionalmente selectivos y composicion farmaceutica | |
AR073412A1 (es) | Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende. | |
CO5640118A2 (es) | 5,7-diaminopirazol[4,3-d]piridinas utiles en el tratamiento de la hipertension | |
AR066121A1 (es) | Derivados de pirimidinona y metodos para su uso | |
AR042996A1 (es) | Un procedimiento de obtencion de derivados de malonamida y medicamentos que los contienen. | |
KR950032180A (ko) | 3-페닐피롤리딘 유도체 | |
HK1097273A1 (en) | Aminopyrones and their use as atm inhibitors | |
AR052824A1 (es) | Derivados de eritromicina | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR044749A1 (es) | Inhibidor de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que lo usan | |
AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
ECSP034611A (es) | Aminotiazoles y su uso como antagonistas del receptor de adenosina | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
CR8755A (es) | Derivado de quinolina fusionada y uso del mismo | |
AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
CO6220970A2 (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos | |
UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
AR061438A1 (es) | Derivados de entacapone | |
AR050341A1 (es) | Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |